Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2013

01-11-2013 | Erratum

Erratum to: CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy

Authors: Wendy A. Teft, Inna Y. Gong, Brian Dingle, Kylea Potvin, Jawaid Younus, Theodore A. Vandenberg, Muriel Brackstone, Francisco E. Perera, Yun-Hee Choi, Guangyong Zou, Robin M. Legan, Rommel G. Tirona, Richard B. Kim

Published in: Breast Cancer Research and Treatment | Issue 1/2013

Login to get access

Excerpt

In the original publication of the article, due to rather complex formulas used, a few of the calculations for predicted endoxifen level may give erroneous values. The correct version of the Electronic Supplementary Material is given in the link below. …
Appendix
Available only for authorised users
Metadata
Title
Erratum to: CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy
Authors
Wendy A. Teft
Inna Y. Gong
Brian Dingle
Kylea Potvin
Jawaid Younus
Theodore A. Vandenberg
Muriel Brackstone
Francisco E. Perera
Yun-Hee Choi
Guangyong Zou
Robin M. Legan
Rommel G. Tirona
Richard B. Kim
Publication date
01-11-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2706-8

Other articles of this Issue 1/2013

Breast Cancer Research and Treatment 1/2013 Go to the issue

Clinical Trial

Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer

Epidemiology

Long-term surveillance mammography and mortality in older women with a history of early stage invasive breast cancer

Brief Report

Distinct nuclear receptor expression in stroma adjacent to breast tumors

Clinical trial

Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer

Preclinical study

Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer

Preclinical Study

Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits